TRAW stock news · Traws Pharma

Stories about Traws Pharma (TRAW) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for TRAW

Follow Traws Pharma (TRAW) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Nov 13, 2026, 9:09 AM ET · Trial
Traws Pharma shared final Phase 2a results for Ratutrelvir, showing fewer side effects and no viral rebounds compared to PAXLOVID®.
Good for TRAW
Traws Pharma reported fewer treatment-related adverse events and no viral rebound versus PAXLOVID® in its final Phase 2a results. The update favors Traws, though FDA discussions are still ahead.
Oct 23, 2026, 5:44 PM ET · Market
Traws Pharma, Inc. has signed an important agreement involving the sale of some of its shares.
Neutral
Traws Pharma filed agreements with Roth that may allow shares to be issued. The filing gives no share count, price, or cash amount, so it does not show a change in the company's outlook.